Bicoll and Genfit announce the identification of active compounds for inflammatory diseases – First candidates de-orphanize nuclear receptor in their joint project OLNORME

Munich (Germany), Lille (France) – September 1, 2009 – BICOLL GmbH, a biopharmaceutical drug
discovery company specializing in high-tech natural product chemistry to identify novel small
molecules for drug discovery and related innovative fields and GENFIT SA (Alternext: ALGFT; ISIN:
FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development,
focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative
diseases, today announce successful preliminary results of their joint research project “OLNORME:
Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites”. First active and
confirmed hits for a class of new drugs were identified and their structures elucidated.